GlassScriptPhysician profile
Dagoberto Camacho
NPI 1629201512
$1,811.96
in general payments reported to CMS, 2019-2025
22 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $231 · 2020: $118 · 2021: $208 · 2022: $556 · 2023: $323 · 2024: $274 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $698.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $698.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $281.03 | 2019-2022 | |
| Lilly USA, LLC | $257.63 | 2022-2023 | Trulicity, Mounjaro, Jardiance |
| Novartis Pharmaceuticals Corporation | $246.92 | 2019-2021 | |
| Dexcom, INC. | $141.58 | 2020-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2021 | |
| Pfizer INC. | $116.90 | 2022-2025 | |
| Exact Sciences Corporation | $90.40 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $76.86 | 2019-2025 | Shingrix, Arexvy, Pediarix |
| Cranial Technologies, INC | $72.69 | 2020-2023 | Doc Band |
| Penumbra, INC. | $66.77 | 2024 | Indigo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.29 | 2022-2023 | Jardiance |
| Renalytix Ai, INC. | $45.99 | 2023-2024 | Kidneyintelx Blood Collection Convenience Kit |
| Seqirus USA INC | $38.08 | 2023-2024 | Flucelvax, Fluad, Flucelvax Quadrivalent |
| Astellas Pharma US INC | $33.46 | 2024 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $32.76 | 2019-2023 | Camzyos |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $24.85 | 2024 | Biopharma Sol - Contract Manuf |
| Actelion Pharmaceuticals US, INC. | $23.77 | 2023 | Uptravi, Opsumit |
| Otsuka America Pharmaceutical, INC. | $22.86 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $20.27 | 2023 | Inpefa |
| Abbott Laboratories | $18.37 | 2024 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $15.75 | 2024 | Gvoke Hypopen |
| Lumibird Medical INC. | $7.73 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dagoberto Camacho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.